Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Dividends are on the rise at Costco, Sanofi, and SAP, three of the world's largest companies with market capitalizations above $100 billion...
MarketBeat·12h ago
More News
Top Analyst Reports for Amazon, Intel & Applied Materials
Amazon drives gains with diverse revenue streams and AI push, but rising costs, debt, and fierce competition cloud its near-term outlook.
Zacks·1d ago
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising competition.
Zacks·2d ago
Managed Asset Portfolios LLC Cuts Stock Position in Sanofi $SNY
Managed Asset Portfolios LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 6.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·2d ago
Sanofi (NASDAQ:SNY) Given Consensus Recommendation of "Hold" by Analysts
Sanofi (NASDAQ:SNY - Get Free Report) has received a consensus recommendation of "Hold" from the fourteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and on...
MarketBeat·4d ago
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?
Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q1 earnings, as new vaccine Capvaxive gains momentum.
Zacks·5d ago
Company News for Apr 24, 2026
Companies In The Article Are: HON,SNY, R and KDP
Zacks·5d ago
Sanofi Q1 Earnings Call Highlights
Sanofi (NASDAQ:SNY) opened 2026 with what interim CEO Olivier Charmeil described as a strong start, pointing to double-digit sales and earnings growth in the first quarter driven by Dupixent, newer...
MarketBeat·5d ago
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Zacks·5d ago
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.